Diffuse midline glioma (DIPG)
H3 K27-altered tumours of the brainstem and midline, with no curative treatment: ONC201 and cell therapy trials.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
All 50 targets, by type of evidence
Ranked by overall score for diffuse midline glioma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 13 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Literature | Clinical |
|---|---|---|---|---|---|
| H3-3A H3.3 histone A | 0.28 | – | 0.46 | ||
| FKBP1A FKBP prolyl isomerase 1A | 0.26 | – | – | ||
| ALDH5A1 aldehyde dehydrogenase 5 family member A1 | 0.26 | – | – | ||
| TP53Peds RMTL tumor protein p53 | 0.19 | – | 0.30 | ||
| EGFRPeds RMTL epidermal growth factor receptor | 0.19 | – | 0.30 | ||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.09 | – | – | ||
| PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma | 0.08 | – | – | ||
| PIK3CDPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | 0.08 | – | – | ||
| PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 | 0.08 | – | – | ||
| PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | 0.08 | – | – | ||
| PIK3R5 phosphoinositide-3-kinase regulatory subunit 5 | 0.08 | – | – | ||
| PIK3R2 phosphoinositide-3-kinase regulatory subunit 2 | 0.08 | – | – | ||
| PIK3R3 phosphoinositide-3-kinase regulatory subunit 3 | 0.08 | – | – | ||
| KDR kinase insert domain receptor | 0.07 | – | – | ||
| FLT4 fms related receptor tyrosine kinase 4 | 0.07 | – | – | ||
| FLT1 fms related receptor tyrosine kinase 1 | 0.07 | – | – | ||
| PDCD1Peds RMTL programmed cell death 1 | 0.07 | – | – | ||
| ODC1Peds RMTL ornithine decarboxylase 1 | 0.06 | – | – | ||
| HDAC9 histone deacetylase 9 | 0.05 | – | – | ||
| IDH1Peds RMTL isocitrate dehydrogenase (NADP(+)) 1 | 0.05 | – | – | ||
| TOP2A DNA topoisomerase II alpha | 0.05 | – | – | ||
| HDAC7 histone deacetylase 7 | 0.05 | – | – | ||
| HDAC2 histone deacetylase 2 | 0.05 | – | – | ||
| HDAC10 histone deacetylase 10 | 0.05 | – | – | ||
| HDAC3 histone deacetylase 3 | 0.05 | – | – | ||
| HDAC6 histone deacetylase 6 | 0.05 | – | – | ||
| HDAC1 histone deacetylase 1 | 0.05 | – | – | ||
| HDAC4 histone deacetylase 4 | 0.05 | – | – | ||
| HDAC8 histone deacetylase 8 | 0.05 | – | – | ||
| HDAC11 histone deacetylase 11 | 0.05 | – | – | ||
| HDAC5 histone deacetylase 5 | 0.05 | – | – | ||
| CDK4Peds RMTL cyclin dependent kinase 4 | 0.04 | – | – | ||
| CD274Peds RMTL CD274 molecule | 0.04 | – | – | ||
| CTLA4Peds RMTL cytotoxic T-lymphocyte associated protein 4 | 0.04 | – | – | ||
| TLR7 toll like receptor 7 | 0.04 | – | – | ||
| CDK6Peds RMTL cyclin dependent kinase 6 | 0.04 | – | – | ||
| TOP2B DNA topoisomerase II beta | 0.04 | – | – | ||
| CD40LG CD40 ligand | 0.03 | – | – | ||
| IDH2Peds RMTL isocitrate dehydrogenase (NADP(+)) 2 | 0.03 | – | – | ||
| NFKBIA NFKB inhibitor alpha | 0.03 | – | – | ||
| ALKPeds RMTL ALK receptor tyrosine kinase | 0.02 | – | – | ||
| MYB MYB proto-oncogene, transcription factor | 0.02 | – | – | ||
| MYBL1 MYB proto-oncogene like 1 | 0.02 | – | – | ||
| POLD2 DNA polymerase delta 2, accessory subunit | 0.02 | – | – | ||
| POLE3 DNA polymerase epsilon 3, accessory subunit | 0.02 | – | – | ||
| POLE DNA polymerase epsilon, catalytic subunit | 0.02 | – | – | ||
| POLA1 DNA polymerase alpha 1, catalytic subunit | 0.02 | – | – | ||
| POLA2 DNA polymerase alpha 2, accessory subunit | 0.02 | – | – | ||
| POLD1 DNA polymerase delta 1, catalytic subunit | 0.02 | – | – | ||
| EML4 EMAP like 4 | 0.02 | – | – |
5 biomarkers in Diffuse midline glioma (DIPG) have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Diffuse Midline Glioma, H3 K27-altered”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 15 accepted items exist; the first 15 were read. This is the published evidence, not treatment advice.
- H3-3A K28M level A
- H3C2 K27M level B
- ACVR1 G328V level B
- ACVR1 Gain-of-Function level B
- ACVR1 Mutation level B